Living with Cancer like a Chronic Disease: Multiple Myeloma | Connie’s Story (3 of 3)

Multiple myeloma is not curable - yet - but it does have so many emerging treatments and combination therapies that continue to get more FDA approval. Connie knows this all too well - she’s been on numerous different treatments and was in two clinical trials at the National Institutes of Health. She addresses the importance of support (and accepting it), and how to focus on one day at a time.

“Take one day at a time. I know that's sort of simplistic, but it is true because if you start focusing too much on the unknown, it won't work. You have to focus on what you've got to do just that day.”

In this Series: Our 3-part series with Connie covers her entire multiple myeloma story, from how she got diagnosed and first-line treatment, to her relapse and continuing different kinds and combinations of therapies, through to quality of life issues and how she lives life with multiple myeloma now. Thank you for sharing your story, Connie!

Video Series:
(1 of 3) How I Got Diagnosed with Cancer (Again): https://youtu.be/gr-YZdZrw4g
(2 of 3) My Cancer Relapse, Newest Treatments & Clinical Trials: https://youtu.be/8IZqrPlE4d0
(3 of 3) Living with Cancer like a Chronic Disease: This Video

Full story & transcript → https://www.thepatientstory.com/living-with-multiple-myeloma-connie-h/

Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story

Contents of this video:
00:00 - Intro
00:37 - Managing the mental, emotional, spiritual
02:13 - Guidance on best kind of support
03:50 - Shifting landscape of multiple myeloma treatments
05:32 - Guidance on how to join a clinical trial
08:40 - What support comes with the clinical trials
10:25 - Importance of patient self-advocacy


#thepatientstory #multiplemyeloma #patientstories #cancerstories #cancerpatient #cancersurvivor #multiplemyeloma #myeloma #RRMM #MMSM #CARTcelltherapy #CART #bloodcancer #clinicaltrials
Be the first to comment